

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2017

<https://marketpublishers.com/r/P5FE6193D0EEN.html>

Date: November 2017

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: P5FE6193D0EEN

Abstracts

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2017

SUMMARY

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Undisclosed which include indications Viral Infections, Hepatitis

B, Solid Tumor, Influenza A Virus, H1N1 Subtype Infections, Liver Cancer, Lymphoma and Unspecified.

The latest report Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2017, outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

The report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all their major and minor projects

The report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) -

Overview

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) -

Companies Involved in Therapeutics Development

Bioncotech Therapeutics SL

Rigontec GmbH

Spring Bank Pharmaceuticals Inc

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug

Profiles

(SB-9200 + HBV nucleoside/tides) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BO-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inarigivir soproxil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Activate DDX58 for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-44 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-9400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-9941 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-9946 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) -

Product Development Milestones

Featured News & Press Releases

Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Induc...

the Second Cohort of Part A of the Phase 2 ACHIEVE Trial

Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference

Oct 06, 2017: Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.

Aug 28, 2017: Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.

May 23, 2017: Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus

May 22, 2017: Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial

May 15, 2017: Spring Bank Pharmaceuticals Announces the Data Safety Monitoring Board Approves Dose Escalation of SB 9200 for the Second Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus

May 03, 2017: Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer

Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B

Apr 21, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 29th International Conference on Antiviral Research

Apr 14, 2016: Spring Bank Pharmaceuticals Presents Data on Immunomodulatory Agent SB 9200 at the 2016 European Association for the Study of the Liver Annual Meeting

Mar 31, 2016: Spring Bank Pharmaceuticals to Present Results from Preclinical Studies of SB 9200 in HBV and HCV at EASL 2016

Feb 23, 2016: Spring Bank Pharmaceuticals Announces Grant of European Patent for SMNH Analogs Including SB 9200

Dec 08, 2015: Spring Bank Pharmaceuticals Reports Preclinical Data on the Use of SB 9200 with Entecavir in the Woodchuck Model of HBV

Nov 16, 2015: Spring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the 2015 American Association for the Study of Liver Diseases Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Bioncotech Therapeutics SL, H2 2017
Pipeline by Rigontec GmbH, H2 2017
Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017
Dormant Projects, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Bioncotech Therapeutics SL

Rigontec GmbH

Spring Bank Pharmaceuticals Inc

I would like to order

Product name: Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/P5FE6193D0EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P5FE6193D0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970